Recent Updates
Recently added Catalysts
GERN Negative Sentiment Score: 35/100

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Key Takeaway: Geron Corporation is under investigation by the Portnoy Law Firm for potential securities fraud, with a class action possibly on the horizon for affected investors. The investigation highlights concerns regarding statements made about the drug Rytelo (imetelstat) and its market potential, where risks related to monitoring requirements and competition were allegedly minimized. Investors are being encouraged to seek legal advice and explore their options for recovering losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation into possible securities fraud may raise concerns about Geron's governance.
  • Class action might indicate significant investor dissatisfaction and loss.
  • Defendants allegedly downplayed risks associated with Rytelo's monitoring requirements.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Geron investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Complaint alleges that, throughout the Class Period, Defendants provided investors with material information regarding the anticipated launch and growth potential of Rytelo (imetelstat). Specifically, the Complaint asserts that Defendants repeatedly expressed confidence in Geron’s ability to capitalize on the purportedly significant unmet medical need for the drug and to execute its commercial plan targeting first-line ESA-ineligible patients, while downplaying or minimizing risks associated with the weekly monitoring requirements for Rytelo, as well as the potential impacts of seasonality and competition on the drug’s sales.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
Attorney Advertising

Tags

Frequently Asked Questions

How can Geron investors contact the law firm?

Investors can reach out to attorney Lesley F. Portnoy via phone at 310-692-8883 or email info@portnoylaw.com.

What is the purpose of the investigation into Geron Corporation?

The investigation aims to look into potential securities fraud involving Geron Corporation.

Is there a cost for investors to discuss their legal rights?

No, discussions about legal rights with the Portnoy Law Firm are free of charge.

What are the main allegations in the Complaint against Geron?

The Complaint alleges misleading statements about Rytelo's potential and risks linked to its sales.

What is the firm's track record in recovering investor losses?

The Portnoy Law Firm has successfully recovered over $5.5 billion for investors in the past.

Last updated: Aug 14, 2025